The PROMISE Study: An Observational Study of Triple Combination Therapy for Cystic Fibrosis

Trial Objective

PROMISE-OB-18 for CFThis is an observational study to evaluate the biological and clinical effects of triple-combination therapy (TCT), elexacaftor/tezacaftor/ivacaftor, in people with cystic fibrosis (CF) before and after starting this therapy, as prescribed by their doctor. Researchers will follow their progress and evaluate the effects of triple-combination therapy in order to understand short and long-term changes caused by the medication to the body and disease.


New enrollment for this trial is temporarily paused

Who Can Participate

Cystic fibrosis patient 12 years or older diagnosed with at least one DF508 CFTR mutation. Must not be using triple-combination therapy before trial.

Age: 12+    Gender: Any Gender

Estimated Time Commitment

6 visits over 25 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Alix Wilson

Alexandra Wilson

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Cystic Fibrosis Foundation (CFF), managed by the Therapeutic Development Network Coordinating Center (TDNCC)

Principal Investigators

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at